Humacyte, Inc. — fact timeline

Humacyte, Inc. entered into Underwriting Agreement with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein valued at approximately $46.80 million (effective 2026-06-10).

“On June 10 , 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”), pursuant to which the Company agreed to issue and sell 47,619,048 shares of the Company’s common stock, $0.0001 par value per share, at a price to the public of $1.05 per share (the “Firm Shares”).”

Humacyte, Inc.: Increased authorized common shares from 350,000,000 to 550,000,000 (effective 2026-06-09).

“The Amendment became effective upon the filing thereof with the Secretary of State of the State of Delaware on June 9, 2026.”

Humacyte, Inc. shareholders approved Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2026-06-09 meeting.

“The stockholders approved the Amendment to increase the number of authorized shares of common stock from 350,000,000 shares to 550,000,000 shares.”

Humacyte, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“The appointment of Pricewaterhouse Coopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Humacyte, Inc. shareholders approved Approval of the Frequency of Future Advisory Votes on Named Executive Officer Compensation at the 2026-06-09 meeting.

“The stockholders approved, on an advisory basis, the holding of advisory vote to approve the compensation paid to the Company’s named executive officers on an annual basis.”

Humacyte, Inc. shareholders approved Approval of Named Executive Officer Compensation at the 2026-06-09 meeting.

“The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as described in the executive compensation section of the proxy statement.”

Humacyte, Inc. shareholders approved Election of Class II directors at the 2026-06-09 meeting.

“The stockholders elected each of the three Class II directors who were nominated to serve until the Company’s 2029 annual meeting of stockholders or until such director’s successor is elected, or until such director’s earlier death, resignation or removal.”

Humacyte, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, th”

Humacyte, Inc. amended Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc. valued at low-single-digit royalties on net sales (effective 2026-04-21).

“On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”), to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”).”

Humacyte, Inc. entered into Placement Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-03-19).

“On March 19, 2026, the Company also entered into a placement agent agreement (the “Placement Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the placement agent (the “Placement Agent”), in connection with the Offering.”

Humacyte, Inc. entered into Purchase Agreements with certain investors valued at 25,000,000 shares ... at a price of $0.80 per share (effective 2026-03-19).

“On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purchase Agreements”) pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share (the “Shares”).”

Humacyte, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at aggregate offering price of up to $60,000,000 (effective 2025-12-16).

“On December 16, 2025, Humacyte, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC, as agent (“TD Cowen”), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60 ,000,000 (the “Shares”) during the term of the Agreement through TD Cowen, acting as agent.”

Humacyte, Inc. terminated Revenue Interest Purchase Agreement with TPC Investments III LP and TPC Investments Solutions LP valued at $38 million cash and 5,725,190 shares of common stock (effective 2025-12-15).

“On December 15, 2025, the Humacyte, Inc. (the “Company”) and Humacyte Global, Inc. (“Global”) agreed with TPC Investments III LP and TPC Investments Solutions LP (collectively, the “Purchasers”), and Hook SA LLC, as agent for the Purchasers (the “Purchasers’ Agent”), to terminate the Revenue Interest Purchase Agreement, dated as of May 12, 2023, as amended (the “Purchase Agreement”), by and among the Company, Global, the Purchasers and the Purchasers’ Agent.”

Humacyte, Inc. entered into Loan Agreement with Avenue Venture Opportunities Fund II, L.P. valued at up to $77,500,000 (effective 2025-12-15).

“On December 15, 2025 (the “Closing Date”), Humacyte, Inc. (the “Company”) and Humacyte Global, Inc. (“Global”, and together with the Company, the “Borrowers”), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the “Loan Agent”) and as lender (“Avenue”), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate”

Humacyte, Inc. issued up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500... and (ii) the applicable Warrant Price of warrant to Avenue Venture Opportunities Fund II, L.P..

“On December 15, 2025, in connection with the Loan Agreement, the Company agreed to issue to Avenue a warrant (the “Warrant”) exercisable for up to a number of shares of Common Stock, equal to the quotient of (i) up to $5,037,500, consisting of (x) $3,412,500 and (y) upon the occurrence of the funding date of the Third Tranche Term Loan, $1,625,000, and (ii) the applicable Warrant Price”

Humacyte, Inc. incurred term loan of $77,500,000 with Avenue Venture Opportunities Fund II, L.P. at greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu maturing December 1, 2029.

“On December 15, 2025 (the "Closing Date"), Humacyte, Inc. (the "Company") and Humacyte Global, Inc. ("Global", and together with the Company, the "Borrowers"), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the "Loan Agreement") with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the "Loan Agent") and as lender ("Avenue"), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate that matures on December 1, 2029, consisting of (i) an initial term loan of $40 million (the "First Tranche Term Loan"), which was fully funded on the Closing Date, (ii) a $12.5 million delayed draw term loan (the "Second Tranche Term Loan") which will be made available between October 1, 2026 and March 31, 2027, subject to the satisfaction of certain revenue, regulatory approvals and liquidity conditions, and (iii) a $25 million delayed draw term loan (the "Third Tranche Term Lo”

Humacyte, Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at up to $80,000,000 (effective 2025-11-21).

“On November 21, 2025, the Company delivered a notice to Jefferies terminating the Agreement, which termination will become effective under the Agreement 10 days thereafter.”

Humacyte, Inc. amended debt with TPC Investments III LP and TPC Investment Solutions LP.

“ith TPC Investments III LP and TPC Investment Solutions LP (collectively, the “Purchasers”) and Hook SA LLC, as agent for”

Humacyte, Inc.: Increased authorized shares of common stock from 250,000,000 to 350,000,000 (effective 2025-06-10).

“At the Annual Meeting, upon the recommendation of the Company’s board of directors, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 250,000,000 to 350,000,000 (the “Amendment”). The Amendment became effective upon the filing thereof with the Secretary of State of the State of Delaware on June 10, 2025.”

Humacyte, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 10, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2024.”

Humacyte, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein valued at approximately $37.4 million (effective 2024-02-29).

“On February 29, 2024, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) of 13,400,000 shares of the Company’s common stock, $0.0001 par value per share, at a price to the public of $3.00 per share (the “Firm Shares”).”

Humacyte, Inc. reported financial results for third quarter ended September 30, 2023.

“On November 9, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2023.”

Humacyte, Inc. reported financial results for the second quarter ended June 30, 2023.

“On August 14, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2023.”

Humacyte, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-07 meeting.

“Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm. The appointment of Pricewaterhouse Coopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of stockholders’ votes on this matter were as follows: For Against Abstain 61,686,786 59,411 14,577 There were no broker non-votes on this proposal.”

Humacyte, Inc. shareholders approved Election of Class II Directors at the 2023-06-07 meeting.

“The stockholders elected each of the four Class II directors who were nominated to serve until the Company’s 2026 annual meeting of stockholders or until such director’s successor is elected, or until such director’s earlier death, resignation or removal. The results of stockholders’ votes on this matter were as follows: Nominee For Withheld Broker Non-Votes Gordon M. Binder 53,072,579 614,973 8,073,222 Todd M. Pope 53,537,054 150,498 8,073,222 Kathleen Sebelius 49,175,215 4,512,337 8,073,222 Rajiv Shukla 52,859,609 827,943 8,073,222”

Humacyte, Inc. reported the first quarter of 2023 results: net income $37.0 million.

“Net loss was $37.0 million for the first quarter of 2023, compared to $19.8 million for the first quarter of 2022.”

Humacyte, Inc. reported financial results for fiscal fourth quarter and full year ended December 31, 2022.

“On March 24, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2022.”

Humacyte, Inc.: The board of directors approved amended and restated bylaws, effective immediately (effective 2022-12-08).

“On December 8, 2022, the board of directors of Humacyte, Inc. (the “Company”) approved amended and restated by laws, which became effective the same day.”

Humacyte, Inc. reported financial results for the third quarter ended September 30, 2022.

“On November 10, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2022.”

C. Bruce Green was appointed as Director at Humacyte, Inc..

“On September 15, 2022, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed C. Bruce Green to the Board.”

Jeffrey H. Lawson resigned as Director at Humacyte, Inc..

“This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Humacyte, Inc. (the "Original Report"), which reported the departure of Jeffrey H. Lawson, M.D., PhD. as the Company's Chief Surgical Officer and Dr. Lawson's resignation from the Company's board of directors, each effective as of the "separation date."”

Jeffrey H. Lawson resigned as Chief Surgical Officer at Humacyte, Inc..

“This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Humacyte, Inc. (the "Original Report"), which reported the departure of Jeffrey H. Lawson, M.D., PhD. as the Company's Chief Surgical Officer and Dr. Lawson's resignation from the Company's board of directors, each effective as of the "separation date."”

Jeffrey H. Lawson resigned as Director at Humacyte, Inc..

“Dr. Lawson also resigned from the Company’s board of directors, effective as of the Separation Date.”

Jeffrey H. Lawson resigned as Chief Surgical Officer at Humacyte, Inc..

“On December 23, 2021, Humacyte, Inc. (the “Company”) and Jeffrey H. Lawson, M.D., Ph.D., the Company’s Chief Surgical Officer, mutually agreed to end Dr. Lawson’s employment with the Company, effective December 31, 2022 (the “Separation Date”).”

William (B.J.) Scheessele was appointed as Chief Commercial Officer at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”

Kiernan T. DeAngelis was appointed as Chief Medical Officer at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”

Jeffrey H. Lawson was appointed as Chief Surgical Officer and Director at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”

William Tente was appointed as Chief Regulatory Officer at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”

Heather Prichard was appointed as Chief Operating Officer at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”

Dale A. Sander was appointed as Chief Financial Officer, Chief Corporate Development Officer and Treasurer at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”

Laura E. Niklason was appointed as President, Chief Executive Officer and Director at Humacyte, Inc..

“Executive Officers Upon consummation of the Business Combination, the following individuals were appointed to serve as executive officers of Humacyte: Name Age Position(s) Laura E. Niklason 58 President, Chief Executive Officer and Director Dale A. Sander 61 Chief Financial Officer, Chief Corporate Development Officer and Treasurer Heather Prichard 44 Chief Operating Officer William Tente 64 Chief Regulatory Officer Jeffrey H. Lawson 57 Chief Surgical Officer and Director Kiernan T. DeAngelis 51 Chief Medical Officer William (B.J.) Scheessele 50 Chief Commercial Officer”